Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 2/2011

01-04-2011 | Review Article

New Interleukin-23 Pathway Inhibitors in Dermatology

Ustekinumab, Briakinumab, and Secukinumab

Authors: Marta Kurzeja, Prof. Lidia Rudnicka, Malgorzata Olszewska

Published in: American Journal of Clinical Dermatology | Issue 2/2011

Login to get access

Abstract

Interleukin (IL)-23 is an important regulator of T helper-17 lymphocytes, which influence the cutaneous immune system by production of IL-17 and several other proinflammatory cytokines. This pathway has been recently linked to the pathogenesis of psoriasis and numerous other skin diseases. A newly developed biologic drug, ustekinumab (CNTO-1275), which targets the p40 subunit of IL-12 and IL-23, was approved by the US FDA and the European Medicines Agency in 2009 for the treatment of moderate to severe psoriasis. Administered as subcutaneous injections of 45 mg at weeks 0 and 4, and then every 12 weeks, ustekinumab produces a 75% improvement in the Psoriasis Area and Severity Index (PASI) in 66.4–75.7% of patients and a Dermatology Life Quality Index (DLQI) score of 0 or 1 in 55–56% of patients after 12 weeks of therapy. A recent clinical trial also indicates the possible efficacy of ustekinumab in psoriatic arthritis.
The proportion of patients who had at least one adverse event through 12 weeks in clinical studies was 51.6–57.6% in the ustekinumab group and 50.4% in the placebo group. Serious adverse events were observed in 1.4–1.6% of patients treated with ustekinumab and in 1.4% of patients receiving placebo. Injection-site reactions occurred in 1–2% of patients and 5% of patients developed anti-ustekinumab antibodies. Further studies are needed to evaluate the long-term efficacy and safety of ustekinumab.
Another biologic drug that targets the same molecules, briakinumab (ABT-874), has recently had its approval application withdrawn in the US and Europe to conduct further analysis and clinical trials. The company plans resubmission at a later date. Other IL-23 pathway inhibitors in the pipeline include anti-p19 monoclonal antibody and apilimod (STA-5326), which interfere with IL-23 activity, as well as secukinumab (AIN-457), LY-2439821, and AMG-827, which exhibit their activity at other targets of the IL-23 pathway.
Literature
1.
Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 antibody, in patients with psoriasis: 76-week results froma randomized, double blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 May; 371 (9625): 1665–74
2.
3.
4.
5.
Kauffman CL, Arai N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004 Dec; 123 (6): 1037–44
6.
Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007 Feb; 356 (6): 580–92
7.
Papp KA, Langley RG, Lebwhol MK, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 antibody, in patients with psoriasis: 52-week results from a randomized, double blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 May 17; 371 (9625): 1675–84
8.
9.
Goriely S, Cavoy R, Goldman M. Interleukin-12 family members and type I interferons in Th17-mediated inflammatory disorders. Allergy 2009 May; 64 (5): 702–9
10.
Goriely S, Neurath MF, Goldman M. How microorganisms tip the balance between interleukin-12 family members. Nat Rev Immunol 2008 Jan; 8 (1): 81–6
11.
D’Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992 Nov; 176 (5): 1387–98
12.
Lyakh L, Trinchieri G, Provezza L, et al. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev 2008 Dec; 226: 112–31
13.
Robertson MJ, Ritz J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1996; 1(1 & 2): 88–97PubMed
14.
Valiante NM, Rengaraju M, Trinchieri G. Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation. Cell Immunol 1992 Nov; 145 (1): 187–98
15.
Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989 Sep 1; 170 (3): 827–45
16.
Jinushi M, Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci 2009 Aug; 100 (8): 1389–96
17.
Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in tumor microenvironment. Cancer Cell 2009 Feb; 15 (2): 114–23
18.
Lankford CS, Frucht DM. A unique role for IL-23 in promoting cellular immunity. J Leukoc Biol 2003 Jan; 73 (1): 49–56
19.
Langrish CL, McKenzie BS, Wilson NJ, et al. IL-12 and IL-23:master regulators of innate and adaptive immunity. Immunol Rev 2004 Dec; 202: 96–105
20.
Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumor incidence and growth. Nature 2006 Jul 27; 442 (7101): 461–5
21.
Kikly K, Liu L, Na S, et al. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006 Dec; 18 (6): 670–5
22.
Mangan PR, Harrington LE, O’Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006 May; 441 (7090): 231–4
23.
Riol-Blanco L, Lazarevic V, Awasthi A, et al. IL-23 receptor regulates unconventional IL-17-producing T cells that control bacterial infections. J Immunol 2010 Feb 15; 184 (4): 1710–20
24.
Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008 Jul 17; 454 (7202): 350–2
25.
Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF beta 1. Expert Rev Dermatol 2007 Feb; 2 (1): 69–78
26.
Liang SC, Tan XY, Luxemberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006 Oct; 203 (10): 2271–9
27.
Mills KH. Induction, function, and regulation of IL-17 producing T-cells. Eur J Immunol 2008 Oct; 38 (10): 2636–49
28.
Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 2009 Dec; 58 (12): 1629–36
29.
Takayashi H, Tsuji H, Hashimoto Y, et al. Serum cytokines and growth factor in Japanese patients with psoriasis. Clin Exp Dermatol 2010 Aug; 35 (6): 645–9
30.
Edwards LJ, Robins RA, Constantinescu CS. Th17/Th1 phenotype in demyelinating disease. Cytokine 2010 Apr; 50 (1): 19–23
31.
Chackerian AA, Chen SJ, Brodie SJ, et al. Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection. Infect Immun 2006 Nov; 74 (11): 6092–9
32.
Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003 Jan; 278 (3): 1910–4
33.
Hong K, Chu A, Lúdvíksson BR, et al. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 1999 Jun; 162 (12): 7480–91
34.
Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol 2009 Feb; 5 (2): 83–91
35.
Krueger G, Ellis NC. Psoriasis: recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005 Jul; 53 (Suppl. 1): S94–100
36.
Torti DC, Feldman R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007 Dec; 57 (6): 1059–68
37.
Lee E, Trepiccho WL, Oestreicher JL, et al. Increased expression of interleukin-23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004 Feb 1; 199 (3): 125–30
38.
Bettelli E, Carrier Y, Gao W, et al. Reciprocal development pathways for the generation of the pathogenic effector TH17 and regulatory T cells. Nature 2006 May 11; 441 (7090): 235–8
39.
Chen Z, O’shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008; 41 (2): 87–102PubMedCrossRef
40.
Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007 Feb 22; 445 (130): 866–72
41.
McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006 Jan; 27 (1): 17–23
42.
Asarch A, Barak O, Loo DS, et al. Th17 cells: a new therapeutic target in inflammatory dermatoses. J Dermatolog Treat 2008; 19 (6): 318–26PubMedCrossRef
43.
Asarch A, Barak O, Loo DS, et al. Th17 cells: a new paradigm for cutaneous inflammation. J Dermatolog Treat 2008; 19 (5): 259–66PubMedCrossRef
44.
Larsen JM, Bonefeld CM, Poulsen SS, et al. IL-23 and Th17-mediated inflammation in human allergic contact dermatitis. J Allergy Clin Immunol 2009 Feb; 123 (2): 286–92
45.
Komura K, Fujimoto M, Hasegawa M, et al. Increased serum interleukin 23 in patients with systemic sclerosis. J Rheumatol 2008 Jan; 35 (1): 120–5
46.
Zhao Y, Balato A, Fishelevich R. Th17/Tc17 infiltration and associated cytokine gene expression in elicitation phase of allergic contact dermatitis. Br J Dermatol 2009 Dec; 161 (6): 1301–6
47.
Shah K, Lee WW, Lee SH, et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 2010 Mar 24; 12 (2): R53
48.
Wong CK, Lit LC, Tam LS, et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008 Jun; 127 (3): 385–93
49.
Kim HR, Kim HS, Park MK, et al. The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand J Rheumatol 2007 Jul-Aug; 36 (4): 259–64
50.
Schmidt C, Giese T, Ludwig B, et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin- 23p19 and interleukin-27p28 in Crohn’s disease but not in ulcerative colitis. Inflamm Bowel Dis 2005 Jan; 11 (1): 16–23
51.
Lew W, Chang JY, Jung JY. Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behçet’s disease. Br JDermatol 2008 Mar; 158 (3): 505–11
52.
Bartlett BL, Tyring SK. Ustekinumab for chronic plaque psoriasis. Lancet 2008 May 17; 371 (9625): 1639–40
53.
Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg 2010 Mar; 29 (1): 48–52
54.
Luo J, Wu SJ, Lacy ER, et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol 2010 Oct 8; 402 (5): 797–812
55.
Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006 Oct; 177 (7): 4917–26
56.
Reddy M, Davis C, Wong J, et al. Modulation of CLA, IL-12R, CD40L, and IL-Ralpha expression and inhibition of IL-12 and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol 2007 May; 247 (1): 1–11
57.
58.
59.
Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patientswith moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010 Oct; 63 (4): 571–9
60.
Sandborn WJ, Feagan BG, Fedorak R, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate- to-severe Crohn’s disease. Gastroenterology 2008 Oct; 135 (4): 1130–41
61.
Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008 Sep; 7 (9): 796–804
62.
Gerdes S, Franke J, Domm S, et al. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol 2010 Nov; 163 (5): 1116–8
63.
Daudén E, Santiago-et-Sánchez-Mateos D, Sotomayor-López E, et al. Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis. Br J Dermatol 2010 Dec; 163 (6): 1346–7
64.
Ruiz Villaverde R, Sánchez Cano D. Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy. Eur J Dermatol 2010 Sep-Oct; 20 (5): 630–1
65.
Wohlrab J, Kreft B. Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol 2010 Sep; 163 (3): 655–6
66.
Balestri R, Bardazzi F, Antonucci A. Should ustekinumab really be used as first-line biological therapy in pityriasis rubra pilaris? Br J Dermatol 2010 Oct; 163 (4): 896–7
67.
68.
Zhou H, Hu C, Zhu Y, et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2010 Mar; 50 (3): 257–67
69.
Chien AL, Elder JT, Ellis CN. Ustekinumab: a new option in psoriasis therapy. Drugs 2009; 69 (9): 1141–52PubMedCrossRef
70.
Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010 Jan 14; 362 (2): 118–28
71.
Griffiths C, Strober B, van der Kerkhof PCM, et al. A phase 3, multicenter, randomized study comparing ustekinumab and etanercept for treatment of moderate to severe plaque psoriasis [abstract no. F1336]. 17th Annual Meeting of the European Academy of Dermatology and Venereology; 2008 Sep 17–20; Paris
72.
Griffiths C, Menter A, Strober B, et al. A phase 3, multicenter, randomized study comparing ustekinumab and etanercept for treatment of moderate to severe plaque psoriasis. 67th Annual Meeting of the American Academy of Dermatology; dy2009 Mar 6-10; San Francisco (CA). J Am Acad Dermatol 2009 Mar; 60 (3 Suppl. 1): AB166
73.
Scanlon JV, Exter BP, Steinberg M, et al. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis. Ann Pharmacother 2009 Sep; 43 (9): 1456–65
74.
Castelo-Soccio L, Van Voorhees AS. Long-term efficacy of biologics in dermatology. Dermatol Ther 2009 Jan-Feb; 22 (1): 22–33
75.
Jiménez-Puya R, Gómez-García F, Amorrich-Campos V, et al. Etanercept: efficacy and safety. J Eur Acad Dermatol Venereol 2009 Apr; 23 (4): 402–5
76.
Rapp SR, Feldman SR, Exum SL, et al. Psoriasis causes as much disability as othermajor medical disorder. J Am Acad Dermatol 1999 Sept; 41 (3 Pt 1): 401–7
77.
Mukhtar R, Choi J, Koo JY. Quality of life issues in psoriasis. Dermatol Clin 2004 Oct; 22 (4): 389–95
78.
Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010 Jan; 162 (1): 137–46
79.
Gottlieb A, Menter N, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double blind, placebo controlled, crossover trial. Lancet 2009 Feb 21; 373 (9664): 633–40
80.
Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003 Dec 15; 198 (12): 1951–7
81.
Rahman P, O’Rielly DD. Psoriatic arthritis: genetic susceptibility and pharmacogenetics. Pharmacogenomics 2008 Feb; 9 (2): 195–205
82.
Hueber AJ, McInnes IB. Immune regulation in psoriasis and psoriatic arthritis: recent developments. Immunol Lett 2007 Dec 15; 114 (2): 59–65
83.
Szodoray P, Alex P, Chappell-Woodward CM, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 2007 Mar; 46 (3): 417–25
84.
Cuchacovich RS, Espinoza LR. Ustekinumab for psoriatic arthritis. Lancet 2009 Feb 21; 373 (9664): 605–6
85.
Slowinska M, Kardynal A, Warszawik O, et al. Alopecia areata developing parallel to improvement of psoriasis during ustekinumab therapy. J Dermatol Case Rep 2010; 4 (1): 15–7PubMedCrossRef
86.
Hölscher C, Atkinson RA, Arendse B, et al. A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol 2001 Dec 15; 167 (12): 6957–66
87.
van de Vosse E, Ottenhoff TH, de Paus RA, et al. Mycobacterium bovis BCG-itis and cervical lymphadenitis due to Salmonella enteritidis in a patient with complete interleukin-12/-23 receptor beta1 deficiency. Infection 2010 Apr; 38 (2): 128–30
88.
Pedraza-Sánchez S, Herrera-Barrios MT, Aldana-Vergara R, et al. Bacille Calmette-Guérin infection and disease with fatal outcome associated with a point mutation in the interleukin-12/interleukin-23 receptor beta-1 chain in two Mexican families. Int J Infect Dis 2010 Sep; 14 Suppl. 3: e256–60
89.
90.
91.
92.
Kaiga T, Sato M, Kaneda H, et al. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol 2007 Jun 15; 178 (12): 7571–80
93.
Kimball AB, Gordon KB, Langley RG, et al., ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008 Feb; 144 (2): 200–7
94.
Kimball A, Zhong J, Valdes J. Retreatment efficacy and long-term safety of the fully human, interleukin-12/-23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial. 67th Annual Meeting of the American Academy of Dermatology; 2009 Mar 6-10; San Francisco (CA). J Am Acad Dermatol 2009 Mar; 60 (3 Suppl. 1): AB168
95.
Gordon K, Langley R, Gottlieb A, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing two dosing regimens of abt-874 to placebo in patients with moderate to severe psoriasis. J Eur Acad Derm Venereol 2010; 24 Suppl. 4: 1–83
96.
Menter A, Gottlieb A, Leonardi C, et al. Efficacy and safety results of ABT-874 vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. J Eur Acad Derm Venereol 2010; 24 Suppl. 4: 1–83
97.
Strober B, Crowley J, Yamauchi P, et al. ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis: efficacy and safety results. J Eur Acad Derm Venereol 2010; 24 Suppl. 4: 1–83
98.
Reich K, Langley R, Papp K, et al. Efficacy and safety of ABT-874 versus methotrexate in patients with moderate to severe psoriasis [abstract]. Annual Meeting of the EADV; 2010 Oct 6-10; Goeteborg: 555
99.
100.
Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010 Oct 6; 2 (52): 52–72
101.
Wada Y, Lu R, Zhou D, et al. Selective abrogation of Th1 response by STA: a potent IL-12/IL-23 inhibitor. Blood 2007 Feb 1; 109 (3): 1156–64
102.
Sands BE, Jacobson EW, Sylwestrowicz T, et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn’s disease. Inflamm Bowel Dis 2010 Jul; 16 (7): 1209–18
103.
Garber K. Immunology’s quiet upheaval. Nature Biotechnol 2009 Aug; 27 (8): 687–9
104.
Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010 Apr; 62 (4): 929–39
105.
Sobell JM, Kalb RE, Weinberg JM. Management of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agents. J Drugs Dermatol 2009 Mar; 8 (3): 230–8
106.
Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther 2009 Jan-Feb; 22 (1): 56–60
Metadata
Title
New Interleukin-23 Pathway Inhibitors in Dermatology
Ustekinumab, Briakinumab, and Secukinumab
Authors
Marta Kurzeja
Prof. Lidia Rudnicka
Malgorzata Olszewska
Publication date
01-04-2011
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 2/2011
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/11538950-000000000-00000

Other articles of this Issue 2/2011

American Journal of Clinical Dermatology 2/2011 Go to the issue

Original Research Article

Resveratrol-Containing Gel for the Treatment of Acne Vulgaris

Therapy In Practice

Nail Disorders in Children

Case Reports

Inverse Psoriasis

Therapy In Practice

Postinflammatory Hyperpigmentation

Leading Article

Malignant Melanoma

Original Research Article

Response to Narrow-Band UVB — Vitiligo-Melasma Versus Vitiligo